Highlights

  • LTR Pharma executed a definitive telehealth distribution agreement with Shed Holdings LLC on 17 July 2026 and a definitive compounding and supply agreement with Strive Specialties Inc. on 20 July 2026.
  • Shed has committed to distributing at least 150,000 units during the first 12 months following commercial launch, with ongoing exclusivity linked to performance.
  • ROXUS in the United States and SPONTAN in Australia continue to reach eligible patients through unapproved medicine access pathways rather than full regulatory marketing approvals.

LTR Pharma Limited (ASX: LTP) has completed an important step in its United States commercialisation strategy by securing definitive agreements covering both the manufacturing and distribution of its intranasal erectile dysfunction therapy, ROXUS. While these agreements establish the commercial framework for launch, they should not be interpreted as regulatory approvals, as the product remains outside the standard FDA approval pathway.

Two Definitive US Agreements Finalised

LTR Pharma announced that it has finalised two separate commercial agreements that replace the previously disclosed binding term sheets announced in June 2026.

On 17 July 2026, the company executed a definitive telehealth distribution agreement with Shed Holdings LLC, a US direct-to-consumer telehealth provider. Three days later, on 20 July 2026, it entered into a definitive compounding and supply agreement with Strive Specialties Inc., which will manufacture and supply ROXUS across the United States.

Together, these agreements establish both the commercial distribution network and pharmacy manufacturing infrastructure required for the planned US rollout of ROXUS.

Shed to Lead Telehealth Distribution

Under the distribution agreement, Shed will market ROXUS through its men's health platform, Mavrox, as well as its broader consumer telehealth network.

LTR Pharma disclosed that Shed has committed to delivering at least 150,000 units during the first 12 months following commercial launch. Continued exclusivity under the agreement depends upon achieving this performance commitment, providing incentives for sustained commercial execution while allowing flexibility if targets are not achieved.

The company views the arrangement as an efficient pathway into the rapidly growing US telehealth market without having to establish its own nationwide sales infrastructure.

Mavrox has already introduced a patient waitlist for ROXUS, signalling commercial preparations ahead of launch, although this does not represent product sales.

Strive Will Manufacture and Supply ROXUS

The second agreement appoints Strive Specialties as the pharmacy responsible for manufacturing, compounding, fulfilment and nationwide distribution of ROXUS.

The agreement also covers technology transfer, sourcing of active pharmaceutical ingredients, quality systems, supply chain management and product change control.

Strive operates as a Section 503A compounding pharmacy under US regulations, enabling customised prescription medicines to be prepared for individual patients. This regulatory framework differs from conventional pharmaceutical approval pathways because compounded medicines are prepared in response to individual prescriptions rather than marketed as FDA-approved finished drug products.

Commercial Agreements Are Not Regulatory Approval

Although the commercial agreements represent meaningful progress, they do not constitute approval by the US Food and Drug Administration.

ROXUS will initially be supplied under the US compounding pharmacy framework rather than through the conventional FDA marketing approval process. Similarly, in Australia, LTR Pharma's lead product SPONTAN remains available only through the Therapeutic Goods Administration's Special Access Scheme rather than general market registration.

These access pathways allow eligible patients to receive prescribed treatments while remaining distinct from formal regulatory approval processes.

As of 27 July 2026, LTR Pharma has established its manufacturing and distribution partners for the United States, but neither ROXUS nor SPONTAN has received full marketing approval in their respective jurisdictions.

SPONTAN Continues Australian Commercial Rollout

SPONTAN is LTR Pharma's intranasal formulation of vardenafil hydrochloride, developed to provide a faster treatment option for erectile dysfunction.

The company states that the formulation can achieve rapid absorption compared with conventional oral therapies. However, the product remains available only through Australia's Special Access Scheme, allowing authorised healthcare practitioners to prescribe the treatment for eligible patients.

Earlier in 2026, LTR Pharma also confirmed ongoing clinical development activities, including recruitment for a Phase II study evaluating the therapy in healthy men aged 65 years and older.

Financial Position and Commercial Opportunity

LTR Pharma remains an early-stage commercial pharmaceutical company with revenues still developing alongside ongoing investment in commercialisation and clinical programs.

The commitment for at least 150,000 units during the first year following commercial launch represents a potentially meaningful commercial opportunity if achieved. However, this commitment begins only after launch, and the company has not yet announced a formal commercial launch date.

Accordingly, future revenue generation will depend on successful execution across manufacturing, distribution, physician prescribing and patient adoption.

What Investors Should Watch

Several milestones remain important over the coming months.

Investors are likely to monitor confirmation of the commercial launch timeline for ROXUS, initial product shipments, commencement of US revenue generation and successful manufacturing readiness following technology transfer to Strive.

Regulatory developments surrounding both ROXUS and SPONTAN will also remain closely watched, particularly any progress toward broader marketing approvals beyond their current access pathways.

Outlook

The execution of two definitive US commercial agreements strengthens LTR Pharma's strategy to enter the growing telehealth-based men's health market while leveraging established distribution and pharmacy partners.

Although the company has successfully secured commercial infrastructure ahead of launch, its products continue to rely on existing pathways for unapproved medicines rather than full regulatory approvals. Future commercial success will therefore depend on effective market execution, physician adoption, patient demand and any future regulatory developments that could expand market access.